Supported by ISIDORe, a phase 2 multicenter clinical trial led by IdiPAZ-FIBHULP (Spain) in collaboration with Oslo University Hospital (Norway) explored the use of CD45RA⁻ memory T cells from convalescent donors to treat hospitalized COVID-19 patients. The trial evaluated the efficacy of adding this adoptive cell therapy to the standard of care (SoC) compared to SoC alone.
Immunoprofiling through CyTOF mass cytometry revealed that patients receiving memory T cells showed faster lymphocyte recovery and significant increases in immune cell subsets such as CD8+ cytotoxic T cells and NK cells—especially in lymphopenic patients. No treatment-related adverse events were observed. These findings suggest that early immune modulation via adoptive T cell infusion can enhance recovery outcomes in severe COVID-19.
Ongoing analysis aims to correlate these immune signatures with clinical outcomes. A manuscript is underway, and results are being disseminated through scientific conferences. This work not only advances COVID-19 treatment strategies but may also inform future interventions for other severe infectious diseases.